shire

is this why our bonus payout changed so dramatically for Mydayis....good luck getting that $1500.... Law360 (July 9, 2018, 7:22 PM EDT) -- The Patent Trial and Appeal Board agreed Friday to review the entirety of two Shire PLC patents covering its long-acting attention deficit hyperactivity...

The US Federal Trade Commission (FTC) has given its nod for the proposed $62 billion acquisition of Shire (SHPG) by Japanese firm Takeda Pharmaceuticals. The merger, the largest ever by a Japanese company, was cleared sans any conditions. Takeda plans to close the acquisition during the first...

Perseverance finally paid off. After four snubs, Takeda succeeded in notching the biggest deal ever in the pharma history by purchasing Shire. Takeda is eager to expand its presence in the U.S. and hence is paying a whopping $62 billion to get a hold of Shire’s drug portfolio...

Round 1: Employee evaluations Flemming Ornskov – Shire CEO approval = 30% Recommend to a friend = 36% Positive business outlook = 28% Company rating = 2.7 / 5.0 Senior management = 2.2 / 5.0 Culture and values = 2.4 / 5.0 Christophe Weber – Takeda CEO approval = 72% Recommend to a friend = 58%...

we can easily absorb vyvanse and mydayis in our bag. Would not need their neuroscience reps. We can promote those drugs in the psych offices we are already in. Shire reps are screwed.

Something is going on and we do not know what it is. As per Q3 results, we are paying DEBT back faster as forecasted, the EPS is in—line with exectations, and the synergies are a few 100mln higher as expected. Why the hell are most of the spendings frozen, in Aug and Dec travel ban, I even did...

Allergan swings to quarterly loss on charges related to Restasis and Teva holding. Given the Federal Court's decision, plans to mitigate the financial impact of generic competition http://alph.st/b68181eb

After selling Restasis patent to Mohawk Indians, Allergan is playing against its opponent Shire. Shire's Xiidra vs. Allergan's Restasis. Who will win?

After selling Restasis patent to Mohawk Indians, Allergan is playing the game very well.

little HQ heads up. Another 15-25 reps gone at the end of Q3.

Shire is systematically eliminating all Baxalta employees. Site and plant closures. Also employees are being notified their jobs will be moving, typically within next 12-16 months. I'm assuming this is to avoid having to notify investors of massive lay offs. Make people leave on their own and...

Can anyone shed some light on this division (Endo/Naptara)? I see a few positions open and wondering if they are due to expansion or people leaving/being fired?